Thrombosis and Haemostasis, Table of Contents Thromb Haemost 1991; 66(01): 006-015DOI: 10.1055/s-0038-1646367 Review Article Schattauer GmbH Stuttgart The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent Blood Coagulation Samuel I Rapaport Recommend Article Abstract PDF Download Buy Article PDF (1116 kb) References References 1 Rapaport SI, Proctor RR, Patch MJ, Yettra M. The mode of inheritance of PTA deficiency: evidence for the existence of major PTA deficiency and minor PTA deficiency. Blood 1961; 18: 149-165 2 Schmaier AH, Silverberg M, Kaplan AP, Colman RW. Contact activation and its abnormalities. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, 2nd Ed.,. edited by Colman RW, Hirsh J, Marder VJ, Salzman EW. Philadelphia: J.B. Lippincott: 1987. p. 18-38 3 Mariani G, Mazzucconi MG. Factor VII congenital deficiency. Haemostasis 1983; 13: 169-177 4 Nemerson Y. The reaction between bovine brain tissue factor and factors VII and X. Biochemistry 1966; 5: 601-608 5 Østerud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation. Proc. Natl. Acad. Sci. USA. 1977; 74: 5260-5264 6 Nemerson Y, Repke D. Tissue factor accelerates the activation of coagulation factor VII: The role of a bifunctional coagulation cofactor. Thromb. Res. 1985; 46: 325-335 7 Rao LVM, Rapaport SI. Activation of factor VII bound to tissue factor: A key early step in the tissue factor pathway of blood coagulation. Proc. Natl. Acad. Sci. USA. 1988; 85: 6687-6691 8 Carrel RW, Christey PB, Boswell DR. Serpins: Antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequences. In: Thrombosis and Haemostasis 1987. edited by Verstraete M, Vermylen J, Lijnen R, Arnout J. Leuven: Leuven University Press: 1987. p. 01-20 9 Marciniak E. Factor Xa inactivation by antithrombin III: evidence for biological stabilization of factor Xa by factor V-phospholipid complex. Br J Haematol 1973; 24: 391-400 10 Comp PC, Esmon CT. Activated protein C inhibits platelet prothrombin-converting activity. Blood 1979; 54: 1271-1281 11 Nesheim ME, Canfield WM, Kisiel W, Mann KG. Studies of the capacity of factor Xa to protect factor Va from inactivation by activated protein C. J. Biol. Chem. 1982; 257: 1443-1447 12 Ellis V, Scully MF, Kakkar VV. Inhibition of prothrombinase complex by plasma proteinase inhibitors. Biochemistry 1984; 23: 5882-5887 13 Hjort PF. Intermediate reactions in the coagulation of blood with tissue thromboplastin. Scan. J. Clin. Lab. Invest. 1957; 9 (suppl 27) p 1-183 14 Seligson U, Kasper CK, Østerud B, Rapaport SI. Activated factor VII: presence in factor IX concentrate and persistence in the circulation after infusion. Blood 1978; 53: 828-837 15 Drake TA, Morrissey JH, Edgington T. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Amer. J. Pathol. 1989; 134: 1087-1097 16 Fleck RA, Rao LVM, Rapaport SI, Varki N. Localization of human tissue factor antigen by immmunostaining with monospecific polyclonal anti-human tissue factor antibody. Thromb. Res. 1990; 57: 765-782 17 Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc. Natl. Acad. Sci. USA 1989; 86: 2839-2843 18 Drake TA, Ruf W, Morrissey JH, Edgington TS. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J. Cell Biol. 1989; 109: 389-395 19 Rao LVM, Hoang AD. Expression of tissue factor in a human ovarian carcinoma cell line. Blood 1989; 74 (suppl) 96a (abstract) 20 Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. Proc. Natl. Acad. Sci. USA 1990; 87: 6995-6999 21 Wun T-C, Kretzmer KK, Girard TJ, Miletich JP, Broze Jr GJ. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandom Kunitz-type inhibitory domains. J. Biol. Chem. 1988; 263: 6001-6004 22 Rao LVM, Rapaport SI. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation. Blood 1987; 69: 645-651 23 Broze Jr GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits Xa: insight into its possible mechanism of action. Blood 1988; 71: 335-343 24 Broze Jr GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546 25 Broze Jr GJ, Girard TJ, Novotny WF. The lipoprotein-associated coagulation inhibitor. In: Progress in Hemostasis and Thrombosis, vol.10,. edited by Coller BS. Philadelphia: W.B. Saunders: 1990. p. 243-268 26 Sanders NL, Bajaj SP, Rapaport SI. A plasma protein that inhibits tissue factor-factor VII activation of factor IX in the presence of factor X. Circulation 1983; Suppl 68: 126a (abstract) 27 Sanders NL, Bajaj SP, Zivelin A, Rapaport SI. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood 1985; 66: 204-212 28 Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63: 1338-1347 29 Hubbard AR, Jennings CA. Inhibition of the tissue factor-factor VII complex: involvement of factor Xa and lipoproteins. Thromb. Res. 1987; 46: 527-537 30 Broze Jr GJ, Miletich JP. Characterization of the inhibition of tissue factor in serum. Blood 1987; 69: 150-155 31 Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition. Thromb. Haemostas. 1988; 60: 453-456 32 Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze Jr GJ. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 1989; 338: 518-520 33 Girard TJ, McPhail LA, Likert KM, Novotny WF, Miletich JP, Broze Jr GJ. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. Science 1990; 248: 1421-1424 34 Warn-Cramer BJ, Maki SL, Zivelin A, Rapaport SI. Partial purification and characterization of the extrinsic pathway inhibitor (the factor Xa-dependent plasma inhibitor of factor VIIa/tissue factor). Thromb. Res. 1987; 48: 11-22 35 Callander NS, Rao LVM, Sandset PM, Warn-Cramer BJ, Rapaport SI. Binding studies of extrinsic pathway inhibitor (EPI) to a cell surface. Blood 1990; 76 (suppl 1) 414a (abstract) 36 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions. J. Biol. Chem. 1990; 265: 16786-16793 37 Haskel EJ, Torr SR, Day KC, Palmier M, Wun TC, Sobel BE, Abendshein DR. Prevention of arterial reocclusion after thrombolysis with lipoprotein-associated coagulation inhibitor (LACI). Circulation 1990; 82 (Suppl III) 2398a (abstract) 38 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J. Biol. Chem. 264 1989; 18832-18837 39 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb. Res. 1987; 47: 389-400 40 Broze Jr GJ, Miletich JP. Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells. Proc. Natl. Acad. Sci. USA 1987; 84: 1886-1890 41 Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: Evidence that endothelium is the principal site of its synthesis. Proc. Natl. Acad. Sci. USA 1990; 87: 8869-8873 42 Warn-Cramer BJ, Maki SL, Rapaport SI. A sulfated rabbit endothelial cell glycoprotein that inhibits factor VIIa/tissue factor is functionally and immunologically identical to rabbit extrinsic pathway inhibitor (EPI). Thromb. Res., in press 43 Warn-Cramer BJ, Maki SL, Rapaport SI. Conserved and divergent properties of rabbit and human extrinsic pathway inhibitor. Circulation 1990; 82 (Suppl III) 0527a (abstract) 44 Novotny WF, Girard TJ, Miletich JP, Broze Jr GJ. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 1988; 72: 2020-2025 45 Novotny WF, Day K, Wun TC, Nieces G. Platelet LACI is present in novel granules. Blood 1990; 76 (suppl. 1) 469a (abstract) 46 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res. 1988; 50: 803-813 47 Novotny WF, Brown SG, Girard TJ, Miletich JP, Broze Jr GJ. Plasma LACI antigen in patient samples. Blood 1989; 74 (suppl. 1) 209a (abstract) 48 Bajaj MS, Rana SV, Wysolmerski RB, Bajaj SP. Inhibitor of the factor VIIa-tissue factor complex is reduced in patients with disseminated intravascular coagulation but not in patients with severe hepatocellular disease. J. Clin. Invest. 1987; 79: 1874-1878 49 Warr TA, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: II Plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 1989; 74: 994-998 50 Warn-Cramer BJ, Almus FE, Rapaport SI. Studies of the factor Xa-dependent inhibitor of factor VIIa/tissue factor (extrinsic pathway inhibitor) from cell supernates of cultured human umbilical vein endothelial cells. Thromb. Haemostas. 1989; 61: 101-105 51 Warr TA, Warn-Cramer BJ, Rao LVM, Rapaport SI. Human plasma extrinsic pathway inhibitor activity: I Standardization of assay and evaluation of physiologic variables. Blood 1989; 74: 201-206 52 Sandset PM, Sirnes PA, Abildgaard U. Factor VII and extrinsic pathway inhibitor in acute coronary disease. Br. J. Haematol. 1989; 72: 391-396 53 Sandset PM, Røise O, Aasen AO, Abildgaard U. Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal cases. Haemostasis 1989; 19: 189-195 54 Sandset PM, Hellgren U, Uvebrandt M, Bergstrom H. Extrinsic pathway inhibitor and heparin cofactor II during normal and hypertension pregnancy. Thromb. Res. 1989; 55: 665-670 55 Abildgaard U, Sandset PM, Andersson TR, Rosen S. The inhibitor of F VIIa in plasma measured with a sensitive chromogenic assay: comparison with antithrombin, protein C, and heparin cofactor II in a clinical material. Folia Hematol. 1988; 115: 278-283 56 Sandset PM, Høgevold HE, Lyberg T, Andersson TR, Abildaard U. Extrinsic pathway inhibitor in elective surgery: A comparison with other coagulation inhibitors. Thromb. Haemostas. 1989; 62: 856-860 57 Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: Changes due to consumption and acute phase reaction. J. Int. Med. 1989; 225: 311-316 58 Brandtzaeg P, Sandset PM, Joe GB, Øvstbø R, Kierulf P, Abildgaard U. Quantitative relation between plasma endotoxin, antithrombin, protein C, extrinsic coagulation pathway inhibitor and fibrinopeptide A in systemic meningococcal disease. Thromb. Res. 1989; 55: 459-470 59 Lindahl AK, Sandset PM, Harbitz T, Andersson T, Abildgaard U. Coagulation inhibitors in patients with advanced cancer disease. Acta Chir. Scand. 1989; 155: 389-3935 60 Rapaport SI. Defibrination Syndromes. In: Hematology, 2nd Ed.. edited by Williams WJ, Beutler E, Erslev AJ, Rundles RW. New York: McGraw-Hill,: 1977. p. 1454-1480 61 Repke D, Gemmell CH, Guha A, Turitto VT, Broze Jr GJ, Nemerson Y. Hemophilia as a defect of the tissue factor pathway of blood coagulation: Effect of factors VIII and IX on factor X activation in a continuous-flow reactor. Proc. Natl. Acad. Sci. USA 1990; 87: 7623-7627 62 Carson SD, Ross SE. Effects of lipid-binding proteins APO A-I, APO A-II, β2-glycoprotein I, and C-Reactive Protein on activation of factor X by tissue factor-factor VIIa. Thromb. Res. 1988; 50: 669-678 63 Funakoshi T, Heimark RL, Hendrickson LE, McMullen BA, Fujikawa K. Human placental anticoagulant protein: Isolation and characterization. Biochemistry 1987; 26: 5572-5578 64 Conkling PR, Patton KL, Hannun YA, Greenberg CS, Weinberg JB. Sphingosine inhibits monocyte tissue factor-initiated coagulation by altering factor VII binding. J. Biol. Chem. 1989; 264: 18440-18444 65 Rapaport SI. Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism. Blood 1989; 73: 359-365 66 Gramzinski RA, Broze Jr GJ, Carson SD. Human fibroblast tissue factor is inhibited by lipoprotein-associated coagulation inhibitor and placental anticoagulant protein but not by apolipoprotein A-II. Blood 1989; 73: 983-989 67 Flaherty MJ, West S, Heimark RL, Fujikawa K, Tait JF. Placental anticoagulant protein-1: Measurement in extracellular fluids and cells of the hemostatic system. J. Lab. Clin. Med. 1990; 115: 174-181 68 Almus FE, Rao LVM, Rapaport SI. Functional properties of factor VIIa/tissue factor formed with purified tissue factor and with tissue factor expressed on cultured endothelial cells. Thromb. Haemostas. 1989; 62: 1067-1073 69 Almus FE, Rao LVM, Fleck RA, Rapaport SI. Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990; 76: 354-360 70 Sandset PM. Studies of extrinsic coagulation pathway inhibitor. Ph.D. thesis 1989; Department of Medicine, Aker Hospital University of Oslo, Oslo, Norway p 23 71 Warr TA, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-1489 72 Sandset PM, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc. Natl. Acad. Sci. USA 1991; 88: 708-712 73 Lerner RG, Rapaport SI, Spitzer JM. Endotoxin-induced intravascular clotting: The need for granulocytes. Thromb. Diath. Haemorrh. 1968; 20: 430-443 74 Rivers RPA, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br. J. Haematol. 1975; 30: 311-31 75 Colucci M, Balconi R, Lorenzet A, Pietra A, Locati D, Donati MB, Semararo N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J. Clin. Invest. 1983; 71: 1893-1896 76 Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone Jr MA. Interleukin 1 (Il-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J. Exp. Med. 1984; 160: 618-623 77 Conkling PR, Greenberg CS, Weinberg JB. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. Blood 1988; 72: 128-133 78 Janco RL, Morris PJ. Regulation of monocyte procoagulant by chemoattractants. Blood 1985; 65: 545-552
